QLT (USA) (QLTI) Releases Earnings Results, Misses Expectations By $-0.32 EPS

QLT (USA) (QLTI) reported quarterly earnings results on Thursday, May-5-2016. The company reported $-0.41 earnings per share for the quarter, missing the analyst consensus estimate by $-0.32. Analysts had a consensus of $-0.09. During the same quarter in the previous year, the company posted $-0.12 EPS.

QLT (USA) closed down -0.04 points or -2.47% at $1.58 with 62,634 shares getting traded on Wednesday. Post opening the session at $1.61, the shares hit an intraday low of $1.58 and an intraday high of $1.68 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

In a different news, on Dec 30, 2015, Jason Aryeh (director) purchased 18,400 shares at $2.49 per share price.

QLT Inc. (QLT) is a biotechnology company engaged in the development and commercialization of ocular products. QLT is engaged in the development of QLT091001 for the treatment of Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP). QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal a biochemical component of the visual retinoid cycle and is used for the treatment of certain age-related and inherited retinal degenerative diseases. The Company’s QLT091001 product candidate has completed a Phase Ib retreatment study for the treatment of LCA and RP a Phase Ib study for the treatment of RP with autosomal dominant mutation in retinal pigment epithelium protein 65 (RPE65) and a Phase IIa study for the treatment of impaired dark adaptation (IDA). QLT091001 has received orphan drug designations for the treatment of LCA and RP by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).


Leave a Reply

QLT (USA) - Is it time to Sell?

Top Brokerage Firms are advising their investors on QLT (USA). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.